A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP)

Trial Profile

A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP)

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2016

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Ceftriaxone; Vancomycin
  • Indications Community-acquired pneumonia; Methicillin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions
  • Sponsors Actavis; Forest Laboratories
  • Most Recent Events

    • 31 May 2016 Results published in Allergan media release.
    • 31 May 2016 According to Allergan media release, the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil), new indications for pediatric patients 2 months of age to less than 18 years of age with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by Streptococcus pneumoniae and other designated susceptible bacteria.
    • 13 Apr 2016 Results published in the Pediatric Infectious Disease Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top